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interactionAbstract In order to increase the scope and utility of small molecule microarrays (SMMs) we have
combined SMMs and SPRi to screen small molecule antagonists against protein targets. Several
small molecules, including immunosuppressive drugs (rapamycin and FK506) and reported inhib-
itors (FOBISIN and Blapsin) of 14-3-3f proteins have been used to validate this technology. Fur-
thermore, a small library of isatin derivatives have been synthesized and screened on developed
platform against 14-3-3f protein. Three molecules, derived from the endogenous intermediate isatin
termed, FZIB-35, FZIB-36 and FZIB-38 were identiﬁed as novel inhibitors which shows signiﬁcant
interaction with 14-3-3f. A mutation in the binding groove of 14-3-3f, (K49E), almost abolishes the
binding of these compounds to 14-3-3f protein. To exclude the probability of false positives, two
more puriﬁed proteins (PtpA and BirA) were also tested. Furthermore, in order to conﬁrm the bind-
ing pocket speciﬁcity, competition assay against R18 peptide was also carried out on presented plat-
form. We show that SMMs in combination with SPRi are a powerful method to identify lead
compounds in high throughput manner without the need to develop an activity based assay.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small molecule microarrays represent valuable tools for high
throughput screening (HTS) in drug discovery (Kuruvilla
et al., 2002) and enable the discovery of important and
unknown protein–ligand interaction resulting in modulation
of protein function (Koehler et al., 2003). SMMs in integration
with cell based assay and confocal laser scanning microscopyurnal of
2 V. Singh et al.(CLSM) have been also described (Darvas et al., 2004; Molna´r
et al., 2013). To date, a number of elegant methods have been
described for screening of small molecule inhibitors against
protein targets. Conventional HTS methods such as TR-
FRET, ﬂuorescence polarization and ALPHAscreen face
daunting challenges due to a number of limitations such as
ﬂuorescence interference, protein labeling, small molecule sol-
ubility, and lengthy analysis times. Therefore, an alternative
label free detection technology can be signiﬁcantly advanta-
geous. A great advantage of SPRi over classical SPR technique
(Redman, 2007) is throughput, allowing the parallel evaluation
of hundreds or thousands of compounds simultaneously (Pillet
et al., 2010). Moreover it provides a rapid identiﬁcation of bio-
molecular interaction along with their kinetic parameters in
real time (Mcdonnell, 2001). A variety of small molecules have
been reported on SPRi for measuring protein–ligand interac-
tion and protein–protein inhibition (Jung et al., 2005; Pillet
et al., 2011). In this article, a combination of SMMs and SPRi
has been used to detect ligand–protein interaction. Different
strategies have been described for developing diverse linker
systems on solid supports capable of anchoring small mole-
cules (Hackler et al., 2003). A selective immobilization strategy
was used for the fabrication of the SMMs through, either
amino or hydroxy functional group of small molecules. Com-
pounds were covalently captured on gold chip through simple
EDC/NHS chemistry linked via PEG chains. Three different
types of experiments were carried out to check the speciﬁcity
of the ligands to the related target and to exclude false posi-
tives. We validate this technology by using the interaction
between FKBP12-Rapa-FK506 and some known inhibitors
of 14-3-3f including the compounds FOBISIN (Zhao et al.,
2011) and Blapsin (Yan et al., 2012). 14-3-3 proteins are a fam-
ily of eukaryotic proteins that can bind to many phosphoser-
ine/phospho-threonine containing signaling proteins such as
kinases, phosphatases, and trans-membrane receptors
(Aitken, 2006). Hundreds of signaling and disease associated
proteins including p53 (Rajagopalan et al., 2010), C-Raf-1
(Molzan et al., 2010), BAD (Jiping et al., 1996), and histone
deacetylases (Wang et al., 2000) have been documented to bind
to 14-3-3 proteins. The dimeric 14-3-3f isoform (Liu et al.,
1996), in particular, is one of the most widely expressed and
plays a major role in apoptosis. Additionally, a recent investi-
gation identiﬁed the f isoform as a biomarker with high spec-
iﬁcity and sensitivity for the diagnosis and prognosis of head
and neck cancer (Macha et al., 2010). Due to the involvement
of 14-3-3 proteins in major cellular processes and diseases, cur-
rent research has shifted toward the discovery of small mole-
cule inhibitors which can provide good therapeutic
opportunities. Over the last decade, a number of small mole-
cule antagonists for 14-3-3 proteins have been studied (Yan
et al., 2012) including some non-peptidic antagonists which
act as inhibitors as well as stabilizers (Milroy et al., 2012). Cur-
rently, there is no reported use of SMMs and SPRi in the dis-
covery of new 14-3-3 proteins inhibitors. The main purpose of
this research is to evaluate the SPRi technology for the screen-
ing of small molecule inhibitors against 14-3-3f. Further, a
small library of compounds derived from isatin, which con-
tained at least one NH2 or OH group were immobilized and
generate small molecule microarrays. Isatin is an endogenous
Indole widely distributed in mammalian brain, peripheral tis-
sue, and body ﬂuids (Medvedev et al., 1996). 14-3-3f represents
one of these targets having speciﬁc and comparatively highPlease cite this article in press as: Singh, V. et al., Small molecule microarray screening
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.020interaction with isatin (Buneeva et al., 2010). Recently, an isat-
in derivative has been reported (ID45) against coxsackievirus
B3 (CVB3) replication (Zhang et al., 2014). The primary
screening of all isatin derivatives results 3 potential hits against
14-3-3f. Four different puriﬁed proteins, FKBP12, PtpA and
BirA including K49E mutant of 14-3-3f were tested against
screened hits followed by competition approach against R18
peptide (Wang et al., 1999) shows promising inhibitory activity
on SPR assay of identiﬁed compounds. In order to validate,
these compounds further tested in ELISA and able to disrupt
14-3-3f interaction with its binding partner PRAS40 protein.
Combination of these two advanced technologies, SMMs
and SPRi provides rapid screening and kinetics parameters
of the tested inhibitors. We believe that this method can be
applied for large scale primary screenings at low cost and with-
out the need to develop an activity assay.
2. Material and methods
2.1. Reagents
Unless otherwise noted, material and solvents were obtained
from commercial suppliers and used without further puriﬁca-
tion. Gold coated slides (Plexera), SH-(PEG)n-COOH (M.W.
1000) and SH-(PEG)n-OH (M.W. 346) (Shanghai Yan Yi bio-
tech.). EDC-HCl (1-(3-Dimethylaminopropyl)-3-ethylcarbodi-
imide hydrochloride) and NHS (N-hydroxy succinimide),
DMAP (N,N-dimethyl amino pyridine) (Aladdin Chemistry).
DMSO, ethanol and ACN (Aldrich). Superblock solution
was ordered from Thermo Scientiﬁc. FOBISIN 101 and FOBI-
SIN 106 were purchased from Sigma. FKBP12 protein was
purchased from Sinobiological Inc. R18 peptide, Blapsin
inhibitors, isatin library (34 compounds) and proteins such
as 14-3-3f, 14-3-3f K49E mutant, PtpA BirA, were obtained
from Prof. Lixin Zhang’s laboratory (Institute of Microbiol-
ogy, Chinese Academy of Sciences). Synthesis procedure and
NMR of identiﬁed inhibitors are presented in supplementary
information.
2.2. SMMs protocol
A schematic representation for the screening process of SMMs
is provided in Fig. 1. Freshly deposited gold coated standard
SPRi chips were cleaned with piranha solution (70% H2SO4/
30% H2O2) for 10 min. The chips were extensively rinsed with
Millipore water for 30 min. The chips were then immersed in
ethanol containing 1 mM solution of SH-(PEG)n-COOH and
SH-(PEG)n-OH (1:10) at 4 C overnight and washed (shaker)
in pure ethanol for 30 min before drying with nitrogen. Here
we used the standard EDC/NHS chemistry for covalent immo-
bilization of the small molecules on the surface of the chips. The
carboxylic group (–COOH) from the SH-PEG-COOH was
modiﬁed with a 1:1 mixture of EDC (0.39 M)/NHS (0.1 M).
N-hydroxy succinimide ester is a robust chemistry widely uti-
lized and able to attack amine and hydroxyl nucleophile groups
(Ma¨dler et al., 2009) of small molecules and form stable amide
and ester bonds respectively. Compounds at 10 mM concentra-
tion in 100%DMSOwere spotted into duplicate using a Genet-
ix Qarray mini printer (contact mode printing) produces
250 lM features, covalently immobilized on the sensor chip
and blocked by superblock solution to minimize non-speciﬁcmethodology based on surface plasmon resonance imaging. Arabian Journal of
Figure 1 Schematic representation of small molecule
microarray.
Figure 2 Identiﬁcation of inhibitors by SPRi (A) SPRi graph
showing interaction of Rapamycin and FK506 with FKBP12
protein with FOBISIN as a negative control and (B) identiﬁcation
of FOBISIN and Blapsin inhibitors against 14-3-3f protein (Rapa
was taken as negative control) on SMMs platform.
Small molecule microarray based on SPRi 3adsorption of proteins on the surface. A typical array image on
a PlexArray HT system (Plexera) is shown in supplementary
Fig. 1. N,N-dimethyl amino pyridine (1 uM) aq. solution was
added to the printing solutions to facilitate nucleophile attack
to form the desired ester bond. The slides were subsequently
washed with DMSO, CAN, DMF, ethanol, PBS and ﬁnally
with distilled water for 30 min respectively to remove non-spe-
ciﬁcally adsorbed compounds.
2.3. SPRi method
All the experiments were carried out using the PlexArray HT
system which is based on surface plasmon resonance imaging
(Guan and Cong, 2007). Small molecules containing at least
one amino or hydroxy functional group are suitable to be
immobilized using this strategy. Puriﬁed recombinant proteins,
FKBP12, 14-3-3f, 14-3-3f (K49E), PtpA and BirA were in PBS
pH 7.4 containing tween 20 (0.05%) and 10% glycerol. Differ-
ent concentrations of proteins were used as analyte. A solution
of NaOH (10 mM) was used to regenerate the surface and
remove bound proteins from the SMMs enabling the sensor
chip to be reused for additional analyte injections. All pre-
sented data were repeated three times to derive the standard
deviations.
2.4. Binding experiments and data analysis
All the stock solutions of small molecules were stored in 100%
dimethyl sulphoxide (DMSO) at 20 C. Protein samples were
stored in PBS with 10% glycerol at 20 C. PBS was used as
both assay and running buffer. A typical sample injection cyclePlease cite this article in press as: Singh, V. et al., Small molecule microarray screening
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.020consists of 200 s association phase with analyte solution and
300 s dissociation phase with running buffer at 3 ul/s ﬂow rate.
Multiple concentrations of each protein 14-3-3f (200, 400 and
600 nM) and FKBP12 (25, 50 and 100 nM) were ﬂowed on the
SPRi instrument as analyte to get accurate kinetic parameters.
Other puriﬁed proteins such as 14-3-3f (K49E), PtpA and BirA
were tested to conﬁrm binding pocket speciﬁcity. The highest
concentration tested for each protein was 600 nM. For data
analysis, we used two software packages: data were analyzed
according to our previous work (Singh et al., 2014). The spe-
ciﬁc binding of protein to the immobilized small molecules
was determined by subtracting the nonspeciﬁc physical adsorp-
tion on reference spots using the Plexera SPR Data Analysis
Module.
3. Results
3.1. High throughput screening of inhibitors by SPR imaging
assay
The microarrays were then blocked and washed before expos-
ing them to the puriﬁed recombinant proteins FKBP12 and 14-
3-3f. As shown in Fig. 2A, the Rapamycin and FK506 spots
bound the FKBP12 protein speciﬁcally. Conversely, FOBISIN
and Blapsin showed speciﬁc binding to 14-3-3f, (Fig. 2B). The
resultant arrays can be regenerated with 10 mM aqueous
NaOH solution and reused several times showing a great
reproducibility. Unrelated compounds and surface back-methodology based on surface plasmon resonance imaging. Arabian Journal of
Figure 3 Identiﬁcation and structure of inhibitors (A) SPRi
graph showing interaction of three identiﬁed inhibitors, FZIB-38,
FZIB-35 and FZIB-36 including R18 as a positive control and
rapamycin as a negative control and (B) chemical structure of
identiﬁed inhibitors.
Figure 4 Screening results against mutant and other unrelated pro
inhibitors and (B) response of new identiﬁed inhibitor toward all target
of 14-3-3f injection shows complete abolishment of binding with kno
inhibitor binds to the speciﬁc pocket of 14-3-3f.
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ensure real binding interactions. Rapamycin and FOBISIN
101 were used as negative and positive control against each
other. The chemical structures of the 14-3-3f (FOBISIN and
Blapsin) hits are shown in (Supplementary Fig. 2). The further
screening of isatin compounds revealed that three reproducible
compounds (FZIB-35, FZIB-36 and FZIB-38) show signiﬁcant
binding (Fig. 3A) to the 14-3-3f protein and no response
against other proteins including FKBP12, BirA and PtpA.
Chemical structures of the isatin hits are shown in Fig. 3B.
3.2. Binding pocket conﬁrmation by SPR imaging assay
In order to test whether these interactions were speciﬁc, we ﬁrst
tested different proteins. In the case of the 14-3-3 inhibitors,
three unrelated recombinant proteins FKBP12, PtpA, and
BirA were tested for binding. These puriﬁed proteins were used
as analytes and passed at the highest concentration (600 nM)
through the SPRi chip to check non-speciﬁc binding. All com-
pounds showed no signiﬁcant binding to PtpA or BirA.
FKBP12 once again shows clear binding to the known immu-
nosuppressive drugs Rapamycin and FK506 (Banaszynski
et al., 2005). This conﬁrms that FKBP12 was folded properly
and it binds speciﬁcally to these compounds but not to the unre-
lated compounds immobilized on the chip (data not shown). As
shown in Fig. 4A and B, all known inhibitors including 3 novel
hits only bind to the 14-3-3f but not to FKBP12, and PtpA or
BirA is supporting the speciﬁcity of these interactions.teins. (A) SPR response of all protein targets to known 14-3-3f
proteins. (C) injection of 14-3-3f protein followed by K49E mutant
wn inhibitors and (D) new isatin inhibitors which indicates that
methodology based on surface plasmon resonance imaging. Arabian Journal of
Figure 5 Competition assay of all 14-3-3f inhibitors (A) sensorgram showing competition assay against R18 peptide. First injection of
14-3-3f followed by two injections of same concentrations in addition to 300 nM and 600 nM of R18 peptide in ﬁrst and second
respectively against known inhibitors and (B) new identiﬁed isatin inhibitors to further conﬁrm speciﬁc pocket phenomenon. (C) Behavior
of 14-3-3f to known inhibitors and (D) identiﬁed inhibitors in completion assay.
Small molecule microarray based on SPRi 5Structural analysis of 14-3-3f has determined that the
amphipathic groove is the primary ligand binding site. The
amphipathic groove lines up with the surface residue which
is conserved between all isoforms of 14-3-3 proteins. Lys-49
is located in the conserved ligand binding site and plays a crit-
ical role in ligand interaction ((Zhang et al., 1997). Charge
reversal mutation K49E in 14-3-3f has shown to decrease its
interaction with Raf-1 kinase and thus with R18 peptide
(Wang et al., 1998). In order to demonstrate that the interac-
tion of 14-3-3f with the aforementioned compounds was via
the speciﬁc binding pocket, we tested the 14-3-3f (K49E)
mutant. Two subsequent injections of 14-3-3f and 14-3-3f
(K49E) separated by single regeneration were ﬂowed on a sin-
gle chip. As shown in Fig. 4C and D the binding of the 14-3-3f
(K49E) mutant to each inhibitor was dramatically reduced to
negligible. This again strongly suggests that, known inhibitors
including novel hits represent bona ﬁde inhibitors that bind to
the primary ligand binding site.
3.3. Competition assay on SPR imaging
To further conﬁrm that the SMMs combined with SPRi can
detect speciﬁc binding events of 14-3-3f toward their inhibitors,
a competition assay based on SPR imaging was developed. R18
is a high afﬁnity peptide antagonist of 14-3-3f protein which
has strong interaction in the range of 70 nM. We used the
R18 peptide as a competitive inhibitor for the immobilized
FOBISIN 101, FOBISIN 106, BLAP1, BLAP2, and BLAP3.
14-3-3f was injected either alone, or in a mixture with two con-Please cite this article in press as: Singh, V. et al., Small molecule microarray screening
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.020centrations of the R18 peptide (Zeta + R18_300 nM and
Zeta + R18_600 nM). In all of three injections (Fig. 5A and
B), the concentrations of 14-3-3f were constant (600 nM).
The mixture containing 300 nM R18 peptide shows a dramatic
reduction in the signal. The binding signal was almost negligi-
ble when the concentration of R18 was increased to 600 nM
(Fig. 5C and D). These data together with the lack of binding
of the 14-3-3f (K49E) mutant to the each inhibitor spots
strongly support the ability of these compounds to disrupt
functional interactions with relevant physiological partners.
3.4. Veriﬁcation by ELISA
To validate and see whether new hits screened from SPRi assay
has some inhibition activity in solution, compounds were
tested in ELISA. ELISA was performed in the same conditions
used in the identiﬁcation of the FOBISIN inhibitor of 14-3-3
protein (see supplementary info.) by Dr. Haian Fu (Zhao
et al., 2011) As a whole, ELISA analysis provides further evi-
dence that these inhibitors can interrupt the interaction of 14-
3-3 with PRAS40 protein (Fig. 6). However their IC50 values
in the low micromolar range, are 3.92, 5.44 and 5.47 for FZIB-
38, FZIB35 and FZIB36 respectively. It is important to note
that the KD values determined by SMM-SPR method are in
general lower than the corresponding IC50 values reported
in the literature for known inhibitors also. This could be due
to either the enhanced afﬁnity of the immobilized inhibitors
on sensor surface or the relatively high concentrations required
for protein–protein in vitro inhibition.methodology based on surface plasmon resonance imaging. Arabian Journal of
6 V. Singh et al.3.5. Kinetics analysis from SPR imaging
Despite the fact that the kinetic parameters can change signiﬁ-
cantly upon the immobilization of the compounds, we mea-
sured the kinetic parameters for all known compounds that
bind FKBP12 and 14-3-3f (Table 1). Here we used global ﬁtting
of a kinetic model in which a 1:1 complex forms between inhib-
itors and target proteins in data analysis module software. The
data ﬁt very well to this model; however, our values for kinetic
rate constants determined from our SPRi experiments for Rap-
amycin and FK506 molecules are signiﬁcantly different from
the ones reported in the literature. This could be due to steric
hindrance caused by the immobilization strategy Kinetics for
known 14-3-3f inhibitors were not available in the literature.
For all 14-3-3f inhibitors, only IC50 values for protein–protein
inhibition have been reported which is based on in vitro (FRET
and FP) assays. As far as we know, this was the ﬁrst time that
the kinetic constants for their binding to 14-3-3f were deter-
mined. The obtained KD values for new identiﬁed isatin inhib-
itors from SPRi assay and IC50 from ELISA presented in
(Table 2). The new identiﬁed inhibitors show a comparable
kinetics from SPRi and IC50 when compared to those from lit-
eratures (Zhao et al., 2011; Yan et al., 2012). This differenceFigure 6 Inhibition of 14-3-3f-PRAS40 (PPIs) interaction by
identiﬁed inhibitors in ELISA.
Table 2 Kinetic parameters and IC50 values of new identiﬁed inhi
Compounds Protein Ka (1/Ms) Kd (1/s)
FZIB-38 14-3-3f 5.07 · 103 2.8 · 10
FZIB-35 14-3-3f 2.94 · 103 2.24 · 10
FZIB-36 14-3-3f 1.64 · 103 2.93 · 10
Table 1 Kinetic parameters of known inhibitors from SPRi.
Compounds Protein Ka (1/Ms)
Rapamycin FKBP12 6.6 · 104
FK506 FKBP12 4.35 · 104
FOBISIN 101 14-3-3f 1.18 · 104
FOBISIN 106 14-3-3f 1.38 · 104
BLAP1 14-3-3f 1.39 · 104
BLAP2 14-3-3f 1.2 · 104
BLAP3 14-3-3f 7.8 · 103
Please cite this article in press as: Singh, V. et al., Small molecule microarray screening
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.020between KD and IC50 is may be due to that IC50 was obtained
for protein–protein inhibition instead of direct measurement
ligands afﬁnity toward the target proteins.
4. Discussion
We have demonstrated here that small molecule microarray
technology is quite useful in combination with surface plasmon
resonance imaging for screening of small molecules modula-
tors against targets of interest. Identiﬁcation of three novel
speciﬁc isatin derived compounds that showed potential utility
as 14-3-3f inhibitors support this methodology. Furthermore,
when these compounds were used in ELISA based 14-3-3f-
PRAS40 binding assay, all three compounds show promising
activity suggested that presented methodology has the poten-
tial to be used in high throughput manner without the need
of development of an activity based assay that in some cases
could be difﬁcult to implement. However, during the course
of this work, we realize that there is still a lot of room for
improvement. Uniformity of spots and signal strength can be
increased by trying different length of PEG linker. Photo-
cross-linkers that bind randomly to any chemical group in a
compound have proved to work well (unpublished data). This
will allow the functional immobilization of larger sets of com-
pounds that lack OH or NH2 groups or for which these groups
are necessary for binding to their targets. Another approach
that facilitates the creation and functionality of SMMs is the
use of 3 dimensional surface chemistries instead of the 2
dimensional surfaces utilized in this work. Although, this plat-
form has some drawbacks at present, it has proved to be suit-
able for screening of FKBP12 and 14-3-3f ligands. Although
this approach can also be used in conjunction with other exist-
ing detection platforms including the use of ﬂuorescence and
microscopic readouts, we believe that the real time kinetics
information gives this methodology a signiﬁcant advantage.
Low reagent requirements and rapid screening time make
SMM technology particularly useful to academic and indus-
trial discovery programs. The speciﬁcity and afﬁnity obtained
on this SMM platform can avoid long, laborious and costly
efforts of primary screening in this ﬁeld. Further developments
on this technology are in progress in our laboratory.bitors from SPRi and ELISA respectively.
KA (1/M) KD (nM) IC50 (lM)
4 1.81 · 107 55.3 ± 2.2 3.92
4 1.31 · 107 76.6 ± 3.8 5.44
4 1.24 · 107 79.6 ± 4.1 5.47
Kd (1/s) KA (1/M) KD (nM)
1.87e3 3.53 · 107 28.2 ± 2.3
2.35e3 5.73 · 107 54.1 ± 2.44
5.64 · 104 2.09 · 107 47.8 ± 2.81
4.94 · 104 2.8 · 107 35.8 ± 2.1
5.54 · 104 2.5 · 107 40 ± 3.92
6.08 · 104 1.97 · 107 50.8 ± 3.76
8.54 · 104 9.14 · 106 109 ± 3.74
methodology based on surface plasmon resonance imaging. Arabian Journal of
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